NADH is NAD⁺ carrying two electrons. They are not rival molecules or competing supplements — they are the same coenzyme in its oxidized (NAD⁺) and reduced (NADH) forms, and your cells convert one into the other continuously to move energy out of food.
So the question a buyer is really asking is not which molecule is better. It is whether a bottle labeled “NADH” does something a bottle labeled NR or NMN does not. On published human evidence, the answer is that the precursors have been studied far more carefully, and the NADH trials that exist are small, old, or confounded by a second ingredient.
What the plus sign actually means
The + in NAD⁺ is a charge, not a brand. The nicotinamide ring in the oxidized form carries a positive charge; when it accepts a hydride — two electrons and a proton — that charge is neutralized and the molecule becomes NADH. Add the electrons, you get NADH. Strip them out, you get NAD⁺ back. Nothing is created or consumed in the exchange.
That cycling is the point. Glycolysis and the citric acid cycle strip electrons out of glucose and fat and park them on NAD⁺; the electron transport chain takes them off NADH and uses them to make ATP, handing back NAD⁺ ready to be loaded again. A cell that ran out of NAD⁺ would stall not because it lacked fuel but because it had nowhere to put the electrons. The same coenzyme also gets consumed outright by sirtuins and PARP enzymes, which is the part of the story our NAD⁺ explainer goes into, and the reason total NAD⁺ can fall at all.
One consequence worth holding on to: the ratio of NAD⁺ to NADH is a regulated quantity, not a scoreboard. Flooding a cell with the reduced form is not obviously the same thing as raising the pool, and no supplement label we have read makes that distinction.
What the NADH trials show
The best-known oral NADH study is a small crossover trial in chronic fatigue syndrome. Twenty-six patients completed four weeks on 10 mg of a stabilized oral NADH and four weeks on placebo. Eight of 26 (31%) responded favorably to NADH against 2 of 26 (8%) on placebo, and the authors described the work as a pilot warranting further trials [1].
A much larger and more recent trial randomized 207 people with myalgic encephalomyelitis/chronic fatigue syndrome to 200 mg of coenzyme Q10 plus 20 mg of NADH (n = 104) or matching placebo (n = 103) for 12 weeks. Cognitive fatigue perception and overall fatigue score fell from baseline within the treated group (p < 0.001 and p = 0.022) [2]. Two things about that are worth noticing before you buy anything: the reported improvements are changes from baseline within the treated group, and NADH was never given on its own — every participant who got NADH also got CoQ10, so the trial cannot tell you which ingredient did what.
Set that against the precursor literature, where an eight-week randomized, placebo-controlled trial of nicotinamide riboside at 100, 300 and 1,000 mg raised whole blood NAD⁺ by 22%, 51% and 142% respectively within two weeks, with the increases maintained for the rest of the study [3]. That is a dose-response curve in a measured biomarker. Nothing on the NADH side is close to it.
Does oral NADH even survive the trip?
This is where the honest answer is “less is known than the labels imply.” NADH is a large, charged, chemically unstable dinucleotide — the same structural problem that stops you from usefully swallowing NAD⁺ itself, which is why the supplement industry sells precursors at all — and why liposomal NAD⁺ products exist to claim they have solved it. Manufacturers address it with stabilized formulations, and the 1999 trial above used one; what has not been published is a head-to-head pharmacokinetic comparison showing that oral NADH raises the NAD⁺ pool the way NR and NMN do.
A systematic review published in early 2026 searched human and rodent intervention studies of NAD-related compounds from January 2010 to October 2025 and identified 113 eligible studies, of which 33 were human intervention studies (28 randomized). Its finding on the oral precursors was consistent target engagement — they raise the measured NAD⁺ metabolites — with heterogeneous and often null effects on the outcomes people actually want [4]. NADH as a standalone oral agent is not what that body of work is about.
What this means if you are choosing a product
If your goal is to raise NAD⁺, the evidence points to a precursor rather than to NADH, and NR versus NMN is the comparison worth making — both have randomized trials behind the biomarker claim. Our oral NAD⁺ supplement board is where those products sit.
If a seller is charging a premium for NADH specifically, on the argument that it is the “active” or “energy” form, treat that as marketing until they show you the trial. And if the same page offers you an injectable or an intravenous version of any of this, the cost gap is enormous and the outcome evidence does not improve with the route.
One last framing that helps: when a clinic says it is “restoring your NAD⁺,” it is talking about the size of the whole pool, not about pushing the pool toward the oxidized or reduced end. Those are different claims, and only the first one has trials.